As rescue therapy for steroid-refractory severe UC, is infliximab or ciclosporin preferred to reduce long-term colectomy rates

What is known

- The retrieved material consists of reference/citation lists from a 2016 systematic review ¹ and discussion sections, which name the key comparative studies, the GETAID randomized trial ^1,2 and the CONSTRUCT trial ^1,2.

What is unknown / caveats

- The provided excerpts do not report comparative outcome data, so it cannot be stated whether infliximab reduces long-term colectomy rates relative to ciclosporin in steroid-refractory severe ulcerative colitis. - The actual colectomy-rate results from those named trials are not contained in these excerpts.

## References

1. Thorne K, Alrubaiy L, Akbari A, Samuel DG, Morrison-Rees S, Roberts SE. Colectomy rates in patients with ulcerative colitis following treatment with infliximab or ciclosporin: a systematic literature review. Eur J Gastroenterol Hepatol. 2016;28(4):369-82. PMID: 26825217.

2. Ollech JE, Normatov I, Peleg N, Dalal SR, Pekow J, Micic D, Cohen RD, Rubin DT, Sakuraba A. Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis. Int J Colorectal Dis. 2020;35(11):2113-2116. PMID: 32710391.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

---

_Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct._